Said T K, Medina D
Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Mol Carcinog. 1998 Jun;22(2):128-43.
To explore the regulation and function of D-type cyclins in breast cancer cells, the mouse mammary hyperplastic epithelial cell line TM2H was treated with 5 mM hexamethylenebisacetamide (HMBA), a polar differentiation factor. The resulting growth-inhibitory effect of HMBA was completely reversible and was analyzed in terms of percent cells in G1; association of D-type cyclins with cyclin-dependent kinase (cdk) 4 and cdk6; G1 kinase activity; association of retinoblastoma protein (pRb) and phosphorylated pRb with D-type cyclins; and association of p16INK4a, p15INK4b, and p27Kip1 with cdk4 and cdk6. Synchronized TM2H cells were examined at 0, 3, 5, 9, 12, and 24 h after exposure to 5 mM HMBA. Inhibition of DNA synthesis, as measured by thymidine uptake, was first observed at 5 h (40%) and peaked at 24 h (80%). Flow cytometry at 9 h showed treated cells to be in G1 arrest. Western blot analysis showed weakly detectable cyclin D1 but readily detectable cyclin D2 and D3 proteins at 0 h; thereafter, cyclin D2 and D3 protein levels remained higher while cyclin D1 levels declined significantly in treated versus untreated cells. By 5 h (early G1), HMBA had markedly inhibited cdk4 and cdk6 kinase activity (67% and 75%, respectively) in treated versus untreated cells. By 9 and 12 h, pRb levels had increased 3.4-fold in treated versus untreated cells. At 5 h, cyclin D-associated pRb was totally hypophosphorylated in treated cells and hyperphosphorylated in untreated cells. The levels of pRb associated with cyclin D2 and D3 increased 2.89-fold and 4.6-fold, respectively, in treated versus untreated cells. At 5 h, treated cells showed a fivefold increase in cdk4-associated p27Kip1 and, at 9 h, a fourfold increase in cdk6-associated p27Kip1 over control levels. In confirmation of these data, HMBA was found to inhibit the growth of Rb-positive Du/145Rb cells but not their Rb-negative parental Du/145 cells. The data suggest that HMBA-induced growth inhibition is due to multifactorial mechanisms involving decreases in total cyclin D1 and inhibition of cdk4 and cdk6 kinase activities through elevation of levels of cdk4- and cdk6-associated p27Kip1 and concomitant increases in hypophosphorylated pRb and stable cyclin D2/pRb and cyclin D3/pRb complexes that help maintain pRb in a functional state.
为了探究D型细胞周期蛋白在乳腺癌细胞中的调控作用及功能,将小鼠乳腺增生上皮细胞系TM2H用5 mM己二甲基双乙酰胺(HMBA)处理,HMBA是一种极性分化因子。HMBA产生的生长抑制作用完全可逆,并从处于G1期的细胞百分比、D型细胞周期蛋白与细胞周期蛋白依赖性激酶(cdk)4和cdk6的结合、G1期激酶活性、视网膜母细胞瘤蛋白(pRb)及磷酸化pRb与D型细胞周期蛋白的结合,以及p16INK4a、p15INK4b和p27Kip1与cdk4和cdk6的结合等方面进行分析。在暴露于5 mM HMBA后的0、3、5、9、12和24小时对同步化的TM2H细胞进行检测。通过胸苷摄取测量的DNA合成抑制在5小时首次观察到(40%),并在24小时达到峰值(80%)。9小时的流式细胞术显示处理后的细胞处于G1期停滞。蛋白质免疫印迹分析显示,在0小时时细胞周期蛋白D1可微弱检测到,但细胞周期蛋白D2和D3蛋白易于检测到;此后,与未处理细胞相比,处理后的细胞中细胞周期蛋白D2和D3蛋白水平保持较高,而细胞周期蛋白D1水平显著下降。到5小时(G1早期),与未处理细胞相比,HMBA显著抑制了处理后细胞中cdk4和cdk6激酶活性(分别为67%和75%)。到9小时和12小时,与未处理细胞相比,处理后细胞中pRb水平增加了3.4倍。在5小时时,处理后细胞中与细胞周期蛋白D相关的pRb完全处于低磷酸化状态,而未处理细胞中则处于高磷酸化状态。与未处理细胞相比,处理后细胞中与细胞周期蛋白D2和D3相关的pRb水平分别增加了2.89倍和4.6倍。在5小时时,处理后细胞中与cdk4相关的p27Kip1增加了五倍,在9小时时,与cdk6相关的p27Kip1比对照水平增加了四倍。为证实这些数据,发现HMBA可抑制Rb阳性的Du/145Rb细胞的生长,但不抑制其Rb阴性的亲本Du/145细胞的生长。这些数据表明,HMBA诱导的生长抑制是由于多因素机制,包括总细胞周期蛋白D1减少、通过提高与cdk4和cdk6相关的p27Kip1水平抑制cdk4和cdk6激酶活性,以及伴随低磷酸化pRb增加和稳定的细胞周期蛋白D2/pRb及细胞周期蛋白D3/pRb复合物增加,这些复合物有助于维持pRb处于功能状态。